hypertension

Among the drugs used in long-term cardiovascular management, carvedilol occupies a special position owing to its combined non-selective beta-blockade and alpha-1 receptor antagonism. However, turning this pharmacological advantage into consistent clinical benefit is not straightforward. The molecule belongs to BCS Class II, meaning it crosses biological membranes readily but barely dissolves in physiological fluids. On top of that, extensive hepatic extraction during the first pass through the liver trims oral bioavailability to somewhere between 25 and 35 percent, and an elimination half-life of only 6 to 10 hours forces patients to take the drug multiple times a day. Together, these characteristics create the conditions for erratic plasma concentrations, missed doses, and avoidable side effects. Encapsulating carvedilol within polymer-matrix microspheres is a strategy with growing experimental support: the polymer network acts as a physical throttle on drug escape, stretching the release window well beyond what any immediate-release tablet can offer. This article brings together evidence published between 2016 and 2025 on how microsphere formulations of carvedilol are built, what polymers are chosen and why, how the finished particles are tested, and what the most informative recent studies have found. Across this body of work, entrapment efficiencies consistently exceed 75 percent when formulation conditions are properly optimised, and release profiles extending to 12 hours or beyond are regularly achieved. Floating, pH-sensitive, and mucoadhesive variants each address specific absorption or tolerability concerns, broadening the design toolbox available to formulators.

Present study aims to prepare and evaluate Metoprolol succinate microspheres by ionotropic gelation method. Among all the formulations S7 was selected as optimized formulations for based on the physico chemical parameters and drug release studies. In the in vitro release study of formulation S7 showed 96.29% after 12 h in a controlled manner, which is essential for disease like peptic ulcer. The in vitro release profiles from optimized formulations were applied on various kinetic models. The best fit with the highest correlation coefficient was observed in Higuchi model, indicating diffusion controlled principle. FT-IR and DSC analyses confirmed the absence of drug-polymer interaction. The results obtained from evaluation and performance study of different types of Metoprolol succinate microspheres that system may be useful to achieve a controlled drug release profile suitable for peroral administration and may help to reduce the dose of drug, dosing frequency and improve patient compliance when compared with marketed product.

Chronopharmaceutics is a branch of pharmaceutics devoted to the design and evaluation of drug delivery systems that release a bioactive agent at a rhythm that ideally matches the biological requirement of a given disease therapy. A major objective of chronotherapy in the treatment of several diseases is to deliver the drug in higher concentrations during the time of greatest need according to the circadian onset of diseases or symptoms. The main objective of the present study is to develop single-unit pulsatile drug delivery system for obtaining no drug release till it reaches in colon followed by pulsed drug release in colon to achieve chronotherapeutic release of atenolol for treatment of hypertension and to improve the patient compliance. In vitro studies revealed that the tablet coated with guar gum and Eudragit S-100 have limited drug release in stomach and small intestinal environment and released maximum amount of drug in the colonic environment. Programmable pulsatile, colon-specific release has been achieved from tablet of T7 formulation (50:50) which meet demand of chronotherapeutic drug delivery. Key Words: pulsatile, chronotherapeutic, hypertension, atenolol